Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai and Sysmex to create new diagnostic aids for dementia

Eisai and Sysmex to create new diagnostic aids for dementia

16th February 2016

Eisai has entered into a comprehensive non-exclusive collaboration agreement with Sysmex in the field of dementia diagnostics.

The companies will be seeking to create next-generation diagnostic reagents with the aim of enabling diagnoses to be made in a manner that is easy, affordable and less invasive than current methods, which include brain scans and cerebrospinal fluid examinations.

Sysmex will leverage its expertise in the field of clinical diagnostics, as well as its portfolio of technologies for the detection of genetic, protein and cellular biomarkers in blood samples. Meanwhile, Eisai will bring its experience of dementia drug discovery to the partnership.

The aim will be to create next-generation diagnostics to enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia.

Sysmex will lead the development of diagnostics and exclusively market these products worldwide after receiving regulatory approval, with Eisai receiving milestone-based payments and the opportunity to utilise these next-generation diagnostics for future drug research.

A statement from Eisai said: "Eisai and Sysmex aim to create new value in prevention, diagnosis and treatment of dementia, and to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients and their families."ADNFCR-8000103-ID-801812652-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.